Calyxt Inc (NASDAQ:CLXT) had a decrease of 2.76% in short interest. CLXT’s SI was 765,700 shares in March as released by FINRA. Its down 2.76% from 787,400 shares previously. With 53,900 avg volume, 14 days are for Calyxt Inc (NASDAQ:CLXT)’s short sellers to cover CLXT’s short positions. The SI to Calyxt Inc’s float is 8.18%. The stock increased 7.34% or $1.32 during the last trading session, reaching $19.23. About 105,621 shares traded or 43.99% up from the average. Calyxt, Inc. (NASDAQ:CLXT) has declined 7.05% since March 20, 2018 and is downtrending. It has underperformed by 11.42% the S&P500. Some Historical CLXT News: 29/05/2018 – Cellectis S.A. Reports 70.6% Stake In Calyxt; 18/05/2018 – CALYXT REPORTS UPSIZING & PRICING OF FOLLOW-ON OFFERING; 22/04/2018 – DJ Calyxt Inc, Inst Holders, 1Q 2018 (CLXT); 12/03/2018 Calyxt Filed Complaint in Delaware Chancery Court Against Bayer CropScience, LP; 30/03/2018 – Consolidated Research: 2018 Summary Expectations for RadNet, Molecular Templates, Federated Investors, Kadant, Heartland Financ; 15/05/2018 – CALYXT INC- UNDER SETTLEMENT, PARTIES AGREED BAYER WILL PERMANENTLY ABANDON PATENT APPLICATIONS BASED ON OR INCLUDE DATA RELATED TO COVERED TECHNOLOGY; 07/05/2018 – CALYXT INC QTRLY SHR LOSS $0.16; 21/03/2018 – Calyxt’s High Fiber Wheat Deemed Non-Regulated by USDA; 18/05/2018 – Calyxt Announces Upsizing and Pricing of Follow-On Offering; 15/05/2018 – CALYXT INC – BAYER CROPSCIENCE LP HAS AGREED TO SETTLE A LAWSUIT BROUGHT BY CALYXT IN DELAWARE CHANCERY COURT
Carmignac Gestion decreased Chemocentryx Inc (CCXI) stake by 5.92% reported in 2018Q4 SEC filing. Carmignac Gestion sold 76,981 shares as Chemocentryx Inc (CCXI)’s stock rose 6.99%. The Carmignac Gestion holds 1.22M shares with $13.36 million value, down from 1.30M last quarter. Chemocentryx Inc now has $588.78M valuation. The stock decreased 1.84% or $0.21 during the last trading session, reaching $11.2. About 170,210 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since March 20, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 ChemoCentryx 4Q EPS 80c; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Calyxt, Inc., an agriculture biotechnology company, develops healthier specialty food ingredients and agricultural food crops using gene editing technology for plants. The company has market cap of $628.14 million. It engages in the development of high oleic soybeans, powdery mildew resistant wheat, cold storable potatoes, high fiber wheat, reduced browning potatoes, and herbicide tolerant wheat. It currently has negative earnings. The Firm was formerly known as Cellectis Plant Sciences, Inc. and changed its name to Calyxt, Inc. in May 2015.
More notable recent Calyxt, Inc. (NASDAQ:CLXT) news were published by: Nasdaq.com which released: “Calyxt (CLXT) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019, also Nasdaq.com with their article: “Pre-Market Earnings Report for March 12, 2019 : MOMO, DKS, NOG, CLXT, INSW, IPI, KEYW, CRBP, DFRG, BGSF, SYBX, SHLO – Nasdaq” published on March 11, 2019, Seekingalpha.com published: “Calyxt, Inc. (CLXT) CEO Jim Blome on Q4 2018 Results – Earnings Call Transcript – Seeking Alpha” on March 12, 2019. More interesting news about Calyxt, Inc. (NASDAQ:CLXT) were released by: Benzinga.com and their article: “Earnings Scheduled For March 11, 2019 – Benzinga” published on March 11, 2019 as well as Benzinga.com‘s news article titled: “5 Stocks Moving In Monday’s After-Hours Session – Benzinga” with publication date: March 11, 2019.
Among 2 analysts covering Calyxt (NASDAQ:CLXT), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Calyxt had 4 analyst reports since February 23, 2019 according to SRatingsIntel. Citigroup maintained Calyxt, Inc. (NASDAQ:CLXT) on Wednesday, February 27 with “Neutral” rating.
Investors sentiment decreased to 0.93 in 2018 Q4. Its down 0.05, from 0.98 in 2018Q3. It dived, as 7 investors sold CCXI shares while 38 reduced holdings. 18 funds opened positions while 24 raised stakes. 27.13 million shares or 1.23% more from 26.80 million shares in 2018Q3 were reported. Ny State Common Retirement Fund holds 0% or 25,400 shares in its portfolio. Smith Asset Group Incorporated Ltd Partnership stated it has 22,897 shares. Bvf Il has 6.69 million shares for 9.54% of their portfolio. Moreover, Legal General Gp Pcl has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 3,615 shares. Cadence Cap Lc invested 0.11% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Farallon Capital Mgmt Llc owns 0.13% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 1.45 million shares. Trexquant Invest Lp owns 0.02% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 33,717 shares. Savings Bank Of Ny Mellon invested in 0% or 139,805 shares. 311,491 are held by Tiaa Cref Investment Management Limited Co. State Street accumulated 487,355 shares or 0% of the stock. Vanguard Gru, a Pennsylvania-based fund reported 1.36M shares. Landscape Cap Management Limited Company accumulated 10,285 shares. State Of Wisconsin Investment Board holds 23,200 shares. 45,500 were accumulated by J Goldman Company Lp. Geode Cap Management Limited Liability Corp holds 0% or 333,917 shares.
Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 4 analyst reports since November 12, 2018 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Tuesday, March 12 by H.C. Wainwright. The firm earned “Buy” rating on Monday, November 12 by Canaccord Genuity. The rating was initiated by Leerink Swann with “Buy” on Thursday, February 14.
Since October 16, 2018, it had 0 insider buys, and 8 selling transactions for $87.64 million activity. The insider Schall Thomas J. sold $447,092. Another trade for 30,237 shares valued at $332,779 was made by Cappel Markus J. on Friday, October 26. KANAYA SUSAN M sold 37,893 shares worth $457,747. GLAXOSMITHKLINE PLC sold 7.34M shares worth $85.85M.